Is Pregabalin Effective for Chronic, Post-Traumatic Neuropathic Pain?

Pregabalin does not appear to be effective for controlling pain in patients with chronic post-traumatic peripheral neuropathic pain (PTNP), according to a study published in the Journal of Neurology.

Pregabalin, an alpha2-delta ligand, is approved in the US for the treatment of neuropathic pain associated with diabetic peripheral neuropathy and spinal cord injury, and for postherpetic neuralgia. In this 15-week, Phase 3, double-blind, placebo-controlled trial, a total of 539 PTNP patients were randomized to receive pregabalin (N=274, flexibly dosed 150–600mg/day) or placebo (N=265). The primary outcome measure was pain rated in a diary completed by telephone each evening; secondary outcomes included measures of overall status, pain-related activity limitation, and sleep.

Based on these findings, the authors concluded that, “The efficacy of pregabalin in PTNP merits further study in light of promising findings in clinically relevant outcomes, the low rate of [serious adverse events], the positive results of a previous trial, established efficacy in other chronic [neuropathic pain] syndromes, and the lack of evidence-based treatments for PTNP.”